Following a large quantity of counterfeits found in the market, the public Myanmar Pharmaceutical Factory (MPF) has decided to re-brand some of its products. Seizure of goods the worth of which amounted to up to over $2 million during last summer has made this decision inevitable.
Fake drugs are particularly dangerous, as they represent a significant risk to the population and at the same time threaten the original brand. Main feature of the trademark, namely, to serve as an assurance of quality and origin, is of the upmost importance when dealing with pharmaceuticals. Efforts in the chase for fake pharmaceutical products in Myanmar have markedly increased in the course of 2016, and the Department of Food and Drug Administration (FDA) has been organizing raids in shops on a regular basis in the past months. Over a third of the visited 300 stores were found to be selling fake products. This staggering number highlights the difficulties which the branches of Burmese administration have in limiting the flow of drugs from neighboring countries, as well as in controlling the products which can be found in the market. Dr. Oakkar Phyo, assistant Director of the FDA has called for tighter cooperation between all agencies in order to solve the health risk run by the population of Myanmar.
One of the last steps in this fight has been the MPF’s decision to protect its products with more complex packaging and a new logo. In order to protect already branded products, holograms will be applied to them in order to easily differentiate them from counterfeits. One may hope that the combined efforts from both drug manufacturers and IP enforcement authorities will be effective in curbing the proliferation of dangerous fake products in the Burmese market.
(Source: The Myanmar Times)